NCT00668057View on ClinicalTrials.gov

BAY38-9456 (Vardenafil HCL Tablet) in ED Treatment for China Registration.

PHASE3CompletedINTERVENTIONAL
Enrollment

624

Participants

Timeline

Start Date

December 31, 2002

Primary Completion Date

September 30, 2003

Study Completion Date

September 30, 2003

Conditions
Erectile Dysfunction
Interventions
DRUG

Levitra (Vardenafil, BAY38-9456)

5 mg Vardenafil orally 1 hour prior to sexual intercourse

DRUG

Levitra (Vardenafil, BAY38-9456)

10 mg Vardenafil orally 1 hour prior to sexual intercourse

DRUG

Levitra (Vardenafil, BAY38-9456)

20 mg Vardenafil orally 1 hour prior to sexual intercourse

DRUG

Placebo

5 mg matching placebo

DRUG

Placebo

10 mg matching placebo

DRUG

Placebo

20 mg matching placebo

Trial Locations (7)

100034

Beijing

100044

Beijing

100083

Beijing

100853

Beijing

200040

Shanghai

200127

Shanghai

310003

Hangzhou

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT00668057 - BAY38-9456 (Vardenafil HCL Tablet) in ED Treatment for China Registration. | Biotech Hunter | Biotech Hunter